Aadvac1
Progressive Non-Fluent Aphasia
Axon Neuroscience SEvaccinePhase 1Dormant
CC
43/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 95/ 100
Competitive context
2 Active assets in the Progressive Non-Fluent Aphasia cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Flortaucipir Mayo Clinic | Phase 4 | BB |
Carbidopa Shirley Ryan AbilityLab | Phase 2/3 | B |
Levodopa Shirley Ryan AbilityLab | Phase 2/3 | B |
Neflamapimod EIP Pharma Inc | Phase 2 | CCC |
Fludeoxyglucose Mayo Clinic | Phase 1 | CC |
Pittsburgh Compound B Unlabelled Mayo Clinic | Phase 1 | CC |
Gosuranemab University of California, San Francisco | Phase 1 | CC |
Same molecule, other indications
Aadvac1 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →